FUNI (Hypha Labs) Short-Term Debt: $0.29 Mil (As of Mar. 2026)


What is Hypha Labs Short-Term Debt?

Hypha Labs FUNI +29.31% Short-Term Debt is $0.29 Mil as of Mar. 2026. The stock has 2 warning signs investors should review.

Hypha Labs's Short-Term Debt for the quarter that ended in Mar. 2026 was $0.29 Mil.

Hypha Labs's quarterly Short-Term Debt declined from Sep. 2025 ($1.62 Mil) to Dec. 2025 ($0.31 Mil) and declined from Dec. 2025 ($0.31 Mil) to Mar. 2026 ($0.29 Mil).

Hypha Labs's annual Short-Term Debt declined from Sep. 2023 ($2.29 Mil) to Sep. 2024 ($1.08 Mil) but then increased from Sep. 2024 ($1.08 Mil) to Sep. 2025 ($1.62 Mil).

Hypha Labs Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Hypha Labs Short-Term Debt Related Terms

Hypha Labs Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Hypha Labs's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hypha Labs Short-Term Debt Chart

Hypha Labs Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.31 1.86 2.29 1.08 1.62

Hypha Labs Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.14 1.48 1.62 0.31 0.29
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of $0.29 Mil mean?
Hypha Labs (FUNI) has a Short-Term Debt of $0.29 Mil as of Mar. 2026.
Is Hypha Labs' Short-Term Debt too high?
Hypha Labs' current Short-Term Debt is $0.29 Mil.
How does Hypha Labs' Short-Term Debt compare to IVRO and PRPH?
Hypha Labs' Short-Term Debt of $0.29 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Medical Diagnostics & Research company?
A good Short-Term Debt depends on the Medical Diagnostics & Research industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Hypha Labs's current Short-Term Debt is $0.29 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hypha Labs stock overvalued right now?
Hypha Labs (FUNI) has a current Short-Term Debt of $0.29 Mil. The current Short-Term Debt is $0.29 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Hypha Labs (FUNI), the current Short-Term Debt is $0.29 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Hypha Labs Business Description

Address 5940 S. Rainbow Boulevard, Las Vegas, NV, USA, 89118
Hypha Labs Inc engaged in the research, development, and commercialization of the Hypha Micropearl accelerator, an in-home, web-based, computer-controlled bioreactor designed to accelerate the production of nutritionally beneficial mushrooms for human consumption. The Company's easy-to-use device, together with replaceable cartridges ordered through its exclusive app, safely and effectively produced enriched mycelium of functional mushrooms, or Micropearls, in eight days. These Micropearls contained active mushroom ingredients in a concentrated, easy-to-handle, tasteless, and odorless form that could be incorporated into various foods and beverages without altering flavor.